Search
Search your stock
Analysis
Novartis AG (NVS)
Novartis AG (NVS)
Ranking:
Buy
Implies positive momentum
Stock Name: Novartis AG
Symbol: NVS
Market Cap: $211.95B
Industry: Drug Manufacturers - General
Sector: Healthcare
Website: https://www.novartis.com
About Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives Please visit their website for more information.

Overview:
Last Close: $107.31
52 Week: $92.57-$120.89
MVA50: 103.84
MVA200: 104.87
Quarterly Revenue: $13.56B
RSI: 58.80
Buy/Sell*: 50.16
1-Month change: 7.76%
3-Month change: -6.99%
EPS: 1.42
*Proprietary Buy Sell Volume Indicator
Price Chart For NVS
Our Approach

Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering various financial parameters of the stock from its income statement, balance sheet, and cash flow, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.

TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.

Contact @ support@theoryofstocks.com

© 2024 Stock Articles. All rights reserved.

This site uses cookies to ensure the best experience. By continuing to use this site, you agree to their use.

Click here for Cookie Policy